The epidemiology of silent and overt strokes in adults with sickle cell disease: a prospective cohort study Save

Date Added
July 20th, 2018
PRO Number
Pro00080248
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders, Stroke
Summary

This is a prospective review study which will follow the routine care adult sickle cell patients will receive to be able to determine the risk of recurrent strokes. Participants will be followed for a minimum of 3.5 years.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE Kids 2) Save

Date Added
May 8th, 2018
PRO Number
Pro00076380
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study will assess the safety and efficacy of voxelotor with long term, daily oral dosing compared to placebo in pediatric participants (ages 9 months to 12 years old) with SCD as measured by improvement in anemia. Participants can expected to be in this study for about 52 weeks with at least 12 visits to the study center.

Institution
MUSC
Recruitment Contact
Joannie Hayes
843-876-8767
hayesj@musc.edu

An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials Save

Date Added
April 10th, 2018
PRO Number
Pro00076264
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This open label extension study is being conducted to assess the long-term safety and efficacy of GBT440 by providing participants from GBT440-031 continued access to treatment with GBT440 after completion of their participation in GBT440-031 and prior to the product potentially being available commercially. All participants enrolled into this study will receive GBT440.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease Save

Date Added
March 13th, 2018
PRO Number
Pro00075374
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study is for patient with Sickle Cell Disease ages 16 to 70. The purpose of this study is to find out if participants with sickle cell disease have a reduction in the symptoms of their disease. Participants can expected to be in this study for about 12 weeks.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Phase IIb Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Disease Save

Date Added
January 9th, 2018
PRO Number
Pro00074247
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study is for patients 18 years and older who have Sickle Cell Disease. The study will be evaluating the safety and tolerability of treatment with riociguat to potentially improvement in blood pressure, blood circulation, and disease symptoms. Participants can expect to be in this study for 20 weeks.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-?0 Thalassemia) Save

Date Added
January 9th, 2018
PRO Number
Pro00074278
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This is for patients aged 18 and older who have Sickle Cell Disease. The main purpose of this study is to find out how safe IMR-687 is for treating people with Sickle Cell, and whether it is has any unwanted effects. Participation in this study will last about 8 months.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis Save

Date Added
October 24th, 2017
PRO Number
Pro00071740
Researcher
Julie Kanter washko

Silhouette
Keywords
Blood Disorders
Summary

This study will assess the efficacy of crizanlizumab in sickle cell disease patients. The study is for male and female subjects between the ages of 18 to 70 who have experienced at least one pain crisis within a 12 month period. The drug is given via an IV infusion in an outpatient setting and consists of 52 visits.

Institution
MUSC
Recruitment Contact
Emily Warner
843-876-8614
warnere@musc.edu

A Family-Centered Self-Management Program for Young Children with Sickle Cell Disease: Phase II Save

Date Added
September 7th, 2017
PRO Number
Pro00068250
Researcher
Shannon Hudson

Silhouette
Keywords
Blood Disorders, Children's Health, Infant, Pediatrics
Summary

This study tests an intervention to help children with sickle cell disease ages 0-7 years and their families. The intervention is available on a smartphone or tablet, and includes an app for keeping track of symptoms and messaging with a health care provider. For more information, please contact Shannon at 843-792-9379.

Institution
MUSC
Recruitment Contact
Shannon Phillips
843-792-9379
phillipss@musc.edu

Self-Management for Families and Youth Living with Sickle Cell Disease - SMYLS Save

Date Added
September 2nd, 2017
PRO Number
Pro00062837
Researcher
Shannon Hudson

Silhouette
Keywords
Blood Disorders, Children's Health, Pediatrics
Summary

The purpose of this study is to find out whether a web-based intervention using a mobile device over a 12-week period is helpful in managing symptoms of Sickle Cell Disease in children, such as pain and fatigue and quality of life. For more information, please contact Shannon at 843-792-9379.

Institution
MUSC
Recruitment Contact
Shannon Phillips
843-792-9379
phillipss@musc.edu

Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC): Needs Assessment and Registry Protocol Save

Date Added
August 8th, 2017
PRO Number
Pro00066242
Researcher
Cathy Melvin

Silhouette
Keywords
Blood Disorders
Summary

iSCENSC is a three-part study that will use new methods (called implementation science) to identify ways to enhance care for people with sickle cell disease (SCD) who are in the (SC)2 South Carolina Sickle Cell network. The (SC)2 network is designed to help more people with SCD find a doctor with training in sickle cell disease and to improve their medical care. Part one of the study is a needs assessment where we look at the current barriers for people with SCD. Part two is a registry for individuals with SCD; and part three will be a study or studies to try and help improve the care for individuals with SCD.

Institution
MUSC
Recruitment Contact
Ashley Green
843-876-8652
greenan@musc.edu

Change_preferences

-- OR --

Create_login